Buckingham Asset Management LLC raised its stake in shares of Allergan PLC. (NYSE:AGN) by 2.6% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 964 shares of the company’s stock after purchasing an additional 24 shares during the quarter. Buckingham Asset Management LLC’s holdings in Allergan PLC. were worth $234,000 at the end of the most recent reporting period.
Other institutional investors also recently modified their holdings of the company. Honeywell International Inc. increased its stake in Allergan PLC. by 13.6% during the 2nd quarter. Honeywell International Inc. now owns 168,130 shares of the company’s stock valued at $40,871,000 after purchasing an additional 20,100 shares in the last quarter. Israel Discount Bank of New York acquired a new position in Allergan PLC. during the 1st quarter valued at approximately $988,000. Palladium Partners LLC increased its stake in Allergan PLC. by 1.7% during the 2nd quarter. Palladium Partners LLC now owns 31,161 shares of the company’s stock valued at $7,575,000 after purchasing an additional 523 shares in the last quarter. Trust Co. of Vermont increased its stake in Allergan PLC. by 62.8% during the 1st quarter. Trust Co. of Vermont now owns 2,875 shares of the company’s stock valued at $687,000 after purchasing an additional 1,109 shares in the last quarter. Finally, Capital Planning Advisors LLC increased its stake in Allergan PLC. by 79.3% during the 1st quarter. Capital Planning Advisors LLC now owns 3,674 shares of the company’s stock valued at $878,000 after purchasing an additional 1,625 shares in the last quarter. Institutional investors and hedge funds own 82.06% of the company’s stock.
AGN has been the topic of several recent research reports. BidaskClub downgraded shares of Allergan PLC. from a “buy” rating to a “hold” rating in a report on Wednesday, August 9th. UBS AG reaffirmed an “outperform” rating and issued a $275.00 price objective on shares of Allergan PLC. in a report on Wednesday, August 9th. Wells Fargo & Company reaffirmed an “outperform” rating and issued a $280.00 price objective (up from $270.00) on shares of Allergan PLC. in a report on Wednesday, August 9th. Cantor Fitzgerald reaffirmed a “hold” rating on shares of Allergan PLC. in a report on Tuesday, August 22nd. Finally, Argus reaffirmed a “buy” rating and issued a $280.00 price objective on shares of Allergan PLC. in a report on Monday, August 14th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and fifteen have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $274.69.
Allergan PLC. (NYSE:AGN) opened at 220.29 on Friday. The firm has a market capitalization of $73.64 billion, a PE ratio of 6.71 and a beta of 1.18. The firm’s 50-day moving average is $231.75 and its 200-day moving average is $236.59. Allergan PLC. has a 52-week low of $184.50 and a 52-week high of $256.80.
Allergan PLC. (NYSE:AGN) last issued its earnings results on Thursday, August 3rd. The company reported $4.02 EPS for the quarter, topping the consensus estimate of $3.95 by $0.07. The company had revenue of $4.01 billion for the quarter, compared to analyst estimates of $3.95 billion. Allergan PLC. had a net margin of 79.17% and a return on equity of 7.37%. The business’s revenue was up 8.8% on a year-over-year basis. During the same period in the previous year, the firm earned $3.35 EPS. On average, analysts anticipate that Allergan PLC. will post $16.25 earnings per share for the current year.
The business also recently announced a quarterly dividend, which was paid on Friday, September 15th. Shareholders of record on Friday, August 18th were given a dividend of $0.70 per share. The ex-dividend date of this dividend was Wednesday, August 16th. This represents a $2.80 annualized dividend and a dividend yield of 1.27%. Allergan PLC.’s payout ratio is currently 9.95%.
Allergan PLC. Company Profile
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.